Verge Genomics

About

Verge Genomics uses machine learning and human genomics to accelerate drug discovery.

San Francisco,California,United States
51 - 100
http://www.vergegenomics.com

Highlights

Details

Last Funding Type: Series A
Last Funding Money Raised: $32M
Industries: Biotechnology,Genetics,Health Care,Machine Learning,Neuroscience
Founded date: Jan 1, 2015
Number Of Employee: 51 - 100
Operating Status: Active
Legal Name: Verge Analytics, Inc.

Verge Genomics transforms drug discovery with artificial intelligence. Verge was founded by a unique combination of the field's top machine learning experts and seasoned neuroscience drug developers. Together, they share the vision that exponential advances in computational genomics combined with new insights into neuroscience has created a breakthrough opportunity to discover drugs that dramatically improve the lives of patients suffering from neurodegenerative disease.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

4

$134.12M

Verge Genomics has raised a total of $134.12M in funding over 2 rounds. Their latest funding was raised on Dec 16, 2021 from a Series B round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Dec 16, 2021	Series B	$98M	10	BlackRock	—	Detail
Jul 17, 2018	Series A	$32M	13	Threshold	—	Detail
Oct 29, 2015	Seed	$4M	10	IA Ventures	—	Detail
Jun 18, 2015	Pre-seed	$120K	1	Y Combinator	—	Detail

Investors

Number of Lead Investors

Number of Investors

4

26

Verge Genomics is funded by 26 investors. BlackRock and IA Ventures are the most recent investors.

Investor Name	Lead Investor	Funding Round
BlackRock	Yes	Series B
IA Ventures	Yes	Seed
Y Combinator	Yes	Pre-seed
ALS Investment Fund	—	Series B
Alumni Ventures	—	Series B
Eli Lilly	—	Series B
Lifeforce Capital	—	Series B
Merck Global Health Innovation Fund	—	Series B
Section 32	—	Series B
Tao Capital Partners	—	Series B